TriangleNEO-COMBATXL (NCT06902376)
NEO-COMBATXL trial for BRAF V600E Wild-Type Anaplastic Thyroid Cancer (NCT06902376). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with anaplastic thyroid cancer that does not carry the BRAF V600E mutation and who are scheduled for surgery.
The idea: before surgery, combine XL092, a daily pill, with the immunotherapy cemiplimab, given by vein every three weeks for three doses. XL092 is taken for eight weeks.
This phase 1 study plans 12 patients and looks at safety and whether the tumor can be completely removed. At UNC Lineberger Comprehensive Cancer Center in Chapel Hill, Siddharth Sheth leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.